Solfarcos seeks US partners for keratin-mimicking peptide technology
The Braga company is also finishing Phase 2a work in Europe on peptide-functionalised liposomal methotrexate for rheumatoid arthritis.
TR
By Tom Reyes · Markets Editor
Sep 17 15:33 ETSource: portugalglobal.pt
The wire
- 01Portuguese biotech Solfarcos is courting US partners to license peptide and protein technology, including the University of Minho-licensed keratin-mimicking peptide used in K18 haircare products acquired by Unilever in 2024.
- 02The company sells licensing and consultancy in peptides and proteins, and says it uses AI-assisted modelling, giving partners another route to peptide formulation know-how.
- 03Its pharmaceutical claim rests on a Phase 2a rheumatoid arthritis program in Europe; no trial data, partner names or deal terms have been disclosed.
From the source
Read at portugalglobal.ptSolfarcos takes K18 peptide technology to the US
Portuguese biotechnology company Solfarcos is seeking new partnerships with US companies to develop innovative peptide- and protein-based products, drawing on the technology behind the development of K18.